Syntonix Pharmaceuticals Report issue

Contributed to NME For profit Phase 1
Founded: Waltham MA United States (1997)
Status: Acquired by Biogen-IDEC (2007)

Organization Overview

First Clinical Trial
2008
NCT00716716
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Syntonix Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 1 Trials (1)

coagulation factor ix (Recombinant), Fc-fusion protein (Alprolix) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemophilia A (Phase 1)

Hemophilia B (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1